Aller au contenu principal
Accès ouvert déclaré 2024 article

68 Ga-FAPI-46 PET/CT in the evaluation of gliomas: comparison with 18 F-FDG PET/CT and contrast-enhanced MRI

21Citations signalées, ce qui n’est pas une note de qualité
6Institutions déclarées
1Pays d’affiliation déclarés

Rattachement africain : cn. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

Rationale: This study compared 68 Ga-FAPI-46 PET/CT, 18 F-fluorodeoxyglucose (FDG) PET/CT, and contrast-enhanced MRI (CE-MRI) for glioma imaging, classification, and recurrence detection and explored PET parameters and molecular pathological profiles.Methods: Between June 2020 and June 2024, we prospectively enrolled patients with space-occupying lesions in the brain or previously treated gliomas.All patients underwent sequential CE-MRI, 68 Ga-FAPI-46, and 18 F-FDG PET/CT.Diagnostic accuracy was assessed based on a reference standard, and PET parameters were analysed for correlations with WHO grading and molecular characteristics.Results: Forty-eight patients (median age, 51 years; 32 men) with 40 confirmed gliomas were enrolled.For primary tumour diagnosis, the sensitivity of 68 Ga-FAPI-46 PET/CT was equivalent to CE-MRI (95% vs. 100%, P = 0.99) and 18 F-FDG PET/CT (95% vs. 77%, P = 0.13).68 Ga-FAPI-46 uptake was higher in grade IV than in grade I-II gliomas (5.03 vs. 1.14, P = 0.02).68 Ga-FAPI-46 PET/CT showed significantly higher maximum standardized uptake value and tumour-to-background ratio (TBR) in recurrent tumours than in treatment-related changes and demonstrated favourable sensitivity and specificity for detecting recurrent gliomas, though not significantly superior to 18 F-FDG PET/CT (sensitivity: 100% vs. 85%, P = 0.48; specificity: 100% vs. 80%, P = 0.99) and CE-MRI (sensitivity: 100% vs. 100%, P = NA; specificity: 100% vs. 40%, P = 0.25).Glial fibrillary acidic protein-mutant gliomas exhibited higher 68 Ga-FAPI-46 uptake than wild-type gliomas.Conclusion: 68 Ga-FAPI-46 PET/CT outperformed 18 F-FDG and CE-MRI in diagnosing glioma recurrence, although the results were not statistically significant.For primary glioma diagnosis, 68 Ga-FAPI-46 PET/CT, despite having a better TBR, did not surpass 18 F-FDG PET/CT and CE-MRI in terms of sensitivity and specificity.However, 68 Ga-FAPI-46 PET/CT is superior to 18 F-FDG for visualizing and classifying gliomas.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé, mais le titre doit être comparé manuellement.

Titre Crossref
<sup>68</sup> Ga-FAPI-46 PET/CT in the evaluation of gliomas: comparison with <sup>18</sup> F-FDG PET/CT and contrast-enhanced MRI
Date Crossref
21/10/2024
Éditeur
Ivyspring International Publisher
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Les institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Peptidase Inhibition and AnalysisProtease and Inhibitor MechanismsUbiquitin and proteasome pathways

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.